FTC alleged AbbVie sued generic companies for patent infringement over their proposed generic version of the testosterone gel, AndroGel, without justifiable grounds but merely to delay the generics. A federal judge in Philadelphia found that AbbVie illegally delayed generic versions of its testosterone replacement drug AndroGel from entering the market and ordered the payment of $448 million in illegal profits to consumers.